The interleukin (IL)-23 inhibitor risankizumab maintains long-term clinical and endoscopic remission in up to 77% of patients with Crohn’s disease who achieve remission with induction treatment, data from a phase 2, open-label study showed.
The results, presented at the 2020 Congress of the European Crohn’s and Colitis Organisation (oral presentation 27), also indicated that 9% and 5% of participants experienced serious and opportunistic infections, respectively, according to the